| A multicenter multinational study of abdominal candidiasis: epidemiology, outcomes and predictors of mortality M Bassetti, E Righi, F Ansaldi, M Merelli, C Scarparo, M Antonelli, ... Intensive care medicine 41, 1601-1610, 2015 | 223 | 2015 |
| Effectiveness of dolutegravir‐based regimens as either first‐line or switch antiretroviral therapy: data from the Icona cohort A Mondi, A Cozzi‐Lepri, A Tavelli, S Rusconi, F Vichi, ... African Journal of Reproduction and Gynaecological Endoscopy 22 (1), 2019 | 63 | 2019 |
| A dual regimen of ritonavir/darunavir plus dolutegravir for rescue or simplification of rescue therapy: 48 weeks’ observational data AF Capetti, MV Cossu, G Orofino, G Sterrantino, G Cenderello, ... BMC Infectious Diseases 17, 1-7, 2017 | 57 | 2017 |
| Efficacy and tolerability of dolutegravir and two nucleos (t) ide reverse transcriptase inhibitors in HIV-1-positive, virologically suppressed patients A Borghetti, G Baldin, A Capetti, G Sterrantino, S Rusconi, A Latini, ... Aids 31 (3), 457-459, 2017 | 52 | 2017 |
| Long-term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multi-centre cohort of HIV-1-infected, virologically suppressed patients G Baldin, A Ciccullo, S Rusconi, A Capetti, G Sterrantino, M Colafigli, ... International journal of antimicrobial agents 54 (6), 728-734, 2019 | 50 | 2019 |
| Efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicentre cohort of patients with suppressed HIV‐1 replication A Borghetti, G Baldin, F Lombardi, A Ciccullo, A Capetti, S Rusconi, ... HIV medicine 19 (7), 452-454, 2018 | 48 | 2018 |
| Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population A Cingolani, A Cozzi Lepri, L Teofili, L Galli, V Mazzotta, GM Baldin, ... PLoS One 12 (10), e0186549, 2017 | 41 | 2017 |
| A comparison between two dolutegravir-based two-drug regimens as switch strategies in a multicentre cohort of HIV-1-infected patients A Ciccullo, G Baldin, A Capetti, S Rusconi, G Sterrantino, G d'Ettorre, ... Antiviral therapy 24 (1), 63-67, 2019 | 40 | 2019 |
| Virological efficacy of dual therapy with lamivudine and dolutegravir in HIV-1-infected virologically suppressed patients: long-term data from clinical practice G Baldin, A Ciccullo, A Borghetti, S Di Giambenedetto Journal of Antimicrobial Chemotherapy 74 (5), 1461-1463, 2019 | 38 | 2019 |
| Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study B Rossetti, G Baldin, G Sterrantino, S Rusconi, A De Vito, A Giacometti, ... Antiviral research 169, 104552, 2019 | 33 | 2019 |
| Efficacy and tolerability of lamivudine plus dolutegravir compared with lamivudine plus boosted PIs in HIV-1 positive individuals with virologic suppression: a retrospective … A Borghetti, F Lombardi, R Gagliardini, G Baldin, A Ciccullo, D Moschese, ... BMC infectious diseases 19, 1-9, 2019 | 31 | 2019 |
| Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting A d’Arminio Monforte, A Cozzi-Lepri, A Di Biagio, G Marchetti, ... Journal of Antimicrobial Chemotherapy 74 (5), 1363-1367, 2019 | 27 | 2019 |
| Virological control and metabolic improvement in HIV-infected, virologically suppressed patients switching to lamivudine/dolutegravir dual therapy A Borghetti, G Baldin, A Ciccullo, R Gagliardini, A D'Avino, A Mondi, ... Journal of Antimicrobial Chemotherapy 71 (8), 2359-2361, 2016 | 26 | 2016 |
| Evolution of major non‐HIV‐related comorbidities in HIV‐infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the … A d'Arminio Monforte, H Diaz‐Cuervo, A De Luca, F Maggiolo, ... HIV medicine 20 (2), 99-109, 2019 | 24 | 2019 |
| Five years with dolutegravir plus lamivudine as a switch strategy: much more than a positive finding A Ciccullo, V Borghi, A Giacomelli, MV Cossu, G Sterrantino, A Latini, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 88 (3), 234-237, 2021 | 23 | 2021 |
| Efficacy and durability of two‐ vs. three‐drug integrase inhibitor‐based regimens in virologically suppressed HIV‐infected patients: Data from real‐life ODOACRE … M Fabbiani, B Rossetti, A Ciccullo, L Oreni, F Lagi, L Celani, M Colafigli, ... HIV medicine 22 (9), 843-853, 2021 | 23 | 2021 |
| Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed … G Baldin, A Ciccullo, A Capetti, S Rusconi, G Sterrantino, MV Cossu, ... HIV medicine 20 (2), 164-168, 2019 | 21 | 2019 |
| Salvage therapy or simplification of salvage regimens with dolutegravir plus ritonavir-boosted darunavir dual therapy in highly cART-experienced subjects: an Italian cohort AF Capetti, G Sterrantino, MV Cossu, G Cenderello, AM Cattelan, ... Antiviral Therapy 22 (3), 257-262, 2017 | 21 | 2017 |
| Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy S Belmonti, F Lombardi, E Quiros-Roldan, A Latini, A Castagna, ... Journal of Antimicrobial Chemotherapy 73 (7), 1949-1954, 2018 | 20 | 2018 |
| Trends of hospitalisations rates in a cohort of HIV-infected persons followed in an Italian hospital from 1998 to 2016 S Bellino, A Borghetti, F Lombardi, L Camoni, A Ciccullo, G Baldin, ... Epidemiology & Infection 147, e89, 2019 | 19 | 2019 |
